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Abstract
Background: This study aims to investigate the effects of a modified, balanced crystalloid including phosphate in a
perioperative setting in order to maintain a stable electrolyte and acid-base homeostasis in the patient.
Methods/design: This is a single-centre, open-label, randomized controlled trial involving two parallel groups of
female patients comparing a perioperative infusion regime with sodium glycerophosphate and Jonosteril®
(treatment group) or Jonosteril® (comparator) alone. The primary endpoint is to maintain a stable concentration of
weak acids [A-] according to the Stewart approach of acid-base balance. Secondary endpoints are measurement of
serum phosphate levels, other acid-base parameters such as the strong ion difference (SID), the onset and severity
of postoperative nausea and vomiting (PONV), electrolyte levels and their excretion in the urine, monitoring of renal
function and glycocalyx components, haemodynamics, amounts of catecholamines and other vasopressors used
and the safety of the infusion regime.
Discussion: Perioperative fluid replacement with the use of currently available crystalloid preparations still fail to
maintain a stable acid-base balance and experts agree that common balanced solutions are still not ideal. This study
aims to investigate the effectivity and safety of a new crystalloid solution by adding sodium glycerophosphate to a
standardized crystalloid preparation in order to maintain a balanced perioperative acid-base homeostasis.
Trial registration: EudraCT number 201002422520. Registered on 30 November 2010.
Keywords: Phosphate, Fluid replacement therapy, Weak acids [A-], Stewart concept, Acid-base balance
Background
The increasing importance of an adequately balanced
crystalloid in terms of outcome has been shown by a range
of review articles [1–4]. Current studies target to find the
“ideal physiologic” crystalloid preparation, resembling
plasma concentrations, maintaining electrolyte concentra-
tions within normal range and stabilizing acid-base bal-
ance. In the beginning of the 1990s it was shown that the
(excessive) administration of isotonic saline resulted in an
acid-base dysbalance, a hyperchloraemic acidosis [5] that
can effectively mask perfusion deficits or result in inad-
equate therapeutic interventions if this condition is mis-
taken as tissue hypoxia [6]. Furthermore, we now know
that a perioperative hyperchloraemic acidosis induced by
administration of saline results in a reduction of renal per-
fusion and/or urinary excretion [7] as well as in a higher
incidence of postoperative nausea and vomiting (PONV)
morbidity and mortality [3, 4, 8–11]. Imbalances in acid-
base chemistry can be described with the help of (1) the
descriptive Henderson-Hasselbalch equation [12], where
the blood pH is related to the bicarbonate buffer system,
(2) a semiquantitative method using the later introduced
concepts of base excess (BE) [13] and anion gap (AG) [14]
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as computable factors and (3) the quantitative physico-
chemical approach by Peter Stewart, which has been
intensively discussed in the 1990s but now has been
mostly accepted to be the “gold standard” [15–17].
The advantage of Stewart’s concept is its quantitative
analytical approach that permits one to diagnose and
differentiate between specific forms of acid-base dis-
turbances that conventional methods have not been
able to describe before [18].
Stewart based his model on three principles: (1) the
sum of all positive charges equals the sum of all nega-
tive charges (principle of electroneutrality), (2) the dis-
sociation equilibria of all incompletely dissociated
substances must always be satisfied and (3) the total
mass of a non-completely dissociated substance can be
calculated by summarizing the amount of dissociated
and non-dissociated forms. Three components comply
to these principles at all times: (1) H2O in its dissoci-
ated form [H+] and [OH−] (however, the plasma
concentration of these ions is extremely low (approxi-
mately 10–7 mmol/l)), (2) strong ions, such as electro-
lytes ([Na+], [K+], [Cl−], [Ca2+], [Mg2+] and lactate,
which are found nearly completely dissociated and can,
therefore, hardly react with other substances in the hu-
man body, and (3) weak (= incompletely dissociated)
substances comprised of acid-base pairs (carbonic acid/
carbon dioxide, NH3/NH4
+) as well as non-volatile
plasma proteins and phosphate [16, 18]. Stewart rigor-
ously distinguished between three dependent variables
the pH and the concentration of hydrogen ions [H+]
and bicarbonate [Bic−] that can only passively respond
to alterations determined entirely by three independent
variables, the carbon dioxide partial pressure (paCO2),
the weak acids [A−] (former [ATOT]) and the strong ion
difference (SID, see below). Stewart also employed the
Henderson-Hasselbalch equation to relate respiratory
acidosis/alkalosis to changes of the paCO2; however, ac-
cording to his model, a metabolic acidosis/alkalosis
cannot be explained with it [16, 18]. Contemplating the
other two independent variables, Stewart proposed that
electrolytes, as well as albumin and phosphate, can shift
the pH; an entirely new perspective. Currently, there
are a couple of formulas proposed to calculate the SID.
For the present study we will use the following formu-
las for [A−] and the SID published by Figge et al. [19]:
SID ¼ ½Naþ þ ½Kþ−ð½Cl− þ ½Lac−Þ ð1Þ
½A− ¼ ½Alb ð0:123 pH−0:631Þ
þ ½Pixð0:309 pH−0:469Þ ð2Þ
where [Na+] = sodium, [K+] = potassium, [Cl−] = chloride,
[Lac−] = lactate, [Alb] = albumin in g/L and
[Pi] = phosphate in mmol/l concentrations in the serum.
Normal values for the SID and [A−] in human plasma
at a pH of 7.4 lie around 40 meq/l and 15 meq/l, re-
spectively. The unit milliequivalents per litre (meq/l) re-
fers to the electric charge (e.g., 2 mmol [Na+] = 2 meq).
Therefore, a normal SID can be calculated with formula
(1) as follows:
SID = (142 meq/l) + (4 meq/l) – (105 meq/l) – (1 meq/
l) = 40 meq/l.
The following relationship between SID, [A−] and the
pH has been established:
SID↑and=or A−½ ↓ → Alkalosis
SID↓and=or A−½ ↑ → Acidosis
Applying this concept, it becomes evident that an in-
crease in chloride lowers the SID, leading to the previ-
ously mentioned hyperchloraemic acidosis and that
hypoalbuminemia lowers [A−], shifting the balance to-
wards an alkalotic state. These new insights into the
cause of different types of metabolic acid-base disorders
comprise the novelty and ingenuity of Stewart’s concept.
Trial rationale and hypothesis
Many crystalloid preparations contain a non-
physiologic concentration of electrolytes. Although
the unprotected term “balanced” is widely used for
different crystalloid preparations by authors and man-
ufacturers, there is currently no perfectly balanced
preparation available. NaCl 0.9% w/v (isotonic saline)
solution consists of 154 mmol/l (=154 meq/l) [Na+]
and 154 mmol/l (= 154 meq/l) [Cl−]. The SID of 0.9%
isotonic saline is, therefore, 0 meq/l. The administra-
tion of large amounts of saline will dilute the patient’s
former physiologic SID resulting in acidosis. Ringer’s
lactate and other balanced solutions show a SID of
27 − 36 meq/l which is much closer to physiologic
values [20, 21]. This was acquired by replacing a
certain amount of chloride with a metabolizable anion
like lactate, acetate or maleate. Though better
balanced than 0.9% isotonic saline, these solutions
neither contain albumin nor phosphate and, thus,
cannot prevent the dilution of [A−] and hence the
possible onset of an alkalotic state if infused in
humans. As a consequence, they are not really
“balanced” in the sense of Stewart’s approach. The
key aspect of the planned investigation is to test the
applicability of a new phosphate-balanced crystalloid
preparation based on Stewart’s concept of acid-base.
The novelty of this study is the fact that sodium
glycerophosphate is administered in patients undergo-
ing major abdominal surgery not to replenish low
phosphate levels as a therapeutic approach, but to
stabilize them pre-emptively.
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We hypothesize that the patients’ [A−] levels can be
stabilized when adding phosphate to a standard crystal-
loid. Additionally, in contrast to the control group, peri-
operative hypophosphatemia can be avoided by the
supplementation of phosphate. It will, therefore, be
tested whether Jonosteril® (Fresenius Kabi AG, Bad
Homburg, Germany, see below) (investigational medical
product 1 (IMP1)) in combination with sodium glycero-
phosphate (Fresenius Kabi AG, Bad Homburg,
Germany) (IMP2)) is able to maintain a more constant
acid-base balance in the patient compared to Jonosteril®
alone. Additionally, a reduction of PONV is possible.
Both preparations are approved substances and
frequently administered during daily clinical routine.
Jonosteril®
The crystalloid Jonosteril® is routinely administered for
perioperative fluid therapy at the authors’ institution. It
contains electrolytes in physiologic concentrations as
well as acetate (Na+ 137 mmol/l, K+ 4 mmol/l, Ca2+
1.65 mmol/l, Mg2+ 1.25 mmol/l, Cl− 110 mmol/l, acet-
ate− 36.8 mmol/l); however, it does not carry albumin
or phosphate. As such, this crystalloid is capable to
maintain a SID within normal range; it will, however,
not be able to prevent a decrease of [A−] due to the oc-
curring dilution [22]. The latter and the decrease of al-
bumin and phosphate will most likely result in
hypoalbuminemia, shifting the system towards alkalosis.
Contraindications for the use of Jonosteril® are any
form of hypersensitivity or allergy to the components
of the crystalloid as well as hyperhidratation and hyper-
kalaemia, according to the manufacturer. Only the crys-
talloid Jonosteril® will be tested in this study, further
studies will be necessary to evaluate the applicability
also for other crystalloid preparations.
Sodium glycerophosphate
Sodium glycerophosphate (Fresenius Kabi AG, Bad
Homburg, Germany; concentration 1 mmol/ml, ATC-
Code: B05XA) is an electrolyte supplement approved
and routinely administered for the parenteral treatment
of hypophosphatemia especially on intensive care units
(ICUs). Phosphate is usually not routinely measured
during surgical procedures and is, therefore, not
substituted. Accordingly, a hypophosphatemia occurs
frequently with an incidence of between 44.8% [23] and
67% [24] and remains undetected, although the un-
favourable effects in terms of post-aggression metabol-
ism are well known. The ATP- dependent metabolism
strongly relies on phosphate as a substrate, especially
during the postoperative phase of major cardiac and ab-
dominal surgery [25, 26]. This leads to a high turnover
of phosphate and requires parenteral substitution.
Therefore, an intraoperative substitution of phosphate
seems reasonable and indicated. It has been shown that
an early perioperative substitution of phosphate during
liver surgery had a protective effect in terms of cardio-
respiratory complication and is, therefore, recom-
mended [27, 28]. Prior to inclusion, all patients will be
evaluated regarding contraindications for the use of
sodium glycerophosphate (existing chronic kidney
disease or renal failure, hyperphosphatemia, hyperna-
tremia or allergic disposition towards sodium glycero-
phosphate or its components). If none of the above can
be detected, the parenteral application of sodium glyc-
erophosphate is uncritical. By contrast to the dosage
given on ICUs [29] or according to an estimated basic
daily demand of 0.2–0.5 mmol/kg bodyweight (accord-
ing to the summary of product characteristics) the
amount of phosphate given during this trial is low. The
maximum infusion rate is 20 mmol phosphate per hour
according to the manufacturer and will not be reached.
It is expected that during the observation period and
due to the substitution, serum phosphate levels will rise
around 0.5 mmol/l [22] which will be controlled every
30 min. Since the substituted phosphate gets rapidly
metabolized and excess phosphate is excreted in the
urine, a severe hyperphosphatemia is not expected [30].
Before initiation of the trial, it was confirmed that
Jonosteril® and sodium glycerophosphate are compat-
ible for the intended use. Phosphate will be added to
Jonosteril® immediately prior to the application to avoid
any potential risk of infection.
Outcome measures
Primary objective
The primary objective is to compare two infusion
therapy regimes, Jonosteril® + Sodium glycerophosphate
(IMP1/IMP2) versus Jonosteril® (IMP1) alone, with the
aim to demonstrate superiority of IMP1/IMP2 over
IMP1 due to a more stable value of [A−] during the
observation period of 120 min after the initiation of
general anaesthesia.
Primary endpoint
The primary endpoint is the calculation of [A−] in
mmol/l according to the Stewart approach of acid-base
balance (using equation (2); numerical deviation from
reference baseline value around 15 meq/l) and takes
place every 30 min over 120 min (time points T1 −T5).
Secondary objectives
The secondary objectives of the trial are the influence of
the distinct infusion therapy regimens on other acid-
base parameters, on the onset of PONV, laboratory
chemical parameters like electrolytes and their excretion
in the urine, as well as hemodynamic stability, monitor-
ing of the vascular barrier (shedding of the glycocalyx),
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the the use of vasopressors and the safety of the crystal-
loid preparation in this setting.
Secondary endpoints of the trial are:
 Serum phosphate levels (ionized in mmol/l, non-
ionized in mg/dl, continuous measure from baseline
T0 and serial blood draws over a 120-min time
frame T1 − T5)
 Acid-base parameters: pH (numerical), paCO2
(mmHg), HCO3
− (mmol/l), BE (mmol/l), anion gap
(mmol/l); (continuous measure from baseline T0 and
serial blood draws over a 120-min time frame T1 −T5)
 Apparent SID and effective SID (both in mmol/l),
Strong Ion Gap (mmol/l), albumin, lactate (ionized
in mmol/l, non-ionized in mg/dl, continuous mea-
sure from baseline measures T0 and serial blood
draws over a 120-min time frame T1 − T5) serum
and urine analysis of electrolytes (osmolality in
mosmol/l; all other in mmol/l, continuous measure
on T6, change from baseline T0)
 Documentation and analysis of mean arterial blood
pressure (MAP) in mmHg, heart frequency in min-1,
demand of vasopressors (norepinephrine dose in
mg/h), stroke volume variation (SVV) in %, central
venous pressure (CVP) in mmHg and cardiac output
in ml/min (continuous measure from baseline T0
and serial blood draws over a 120-min time frame
T1–T5)
 Assessment of serum creatinine (mg/dl) and urea
(mg/dl) as well as calculation of the glomerular
filtration rate (ml/min) and creatinine clearance
(Ccr) in ml/min according to the Cockroft-Gault
equation [31] as continuous measure on two blood
draws at T0 and T6, change from baseline T0)
Ccr ¼ 140−Age in yearsð Þ  Mass in kgð Þ  0:85 if female½ 72  Serum Creatinine in mg=dlð Þ
 Monitoring of the integrity of the vascular barrier
function via detection of hyaluronic acid and
syndecan-1 (shedding of glycocalyx components)
(in ng/ml, continuous measure from baseline T0 and
serial blood draws over a 120-min time frame T1–T5)
 Evaluation and documentation of postoperative
nausea and vomiting (descriptive evaluation on day
of surgery until postoperative day 3, patients’
account and anaesthesia protocol of surgery,
dichotomic measure: yes/no)
 Onset frequency and intensity of unexpected events:
UE/ SUE and SUSARs (critical assessment on day of
surgery T1–T5 until postoperative day 3, onset: date,
severity score 1–3: mild, moderate, severe, according
to detailed injury reporting plan)
 Necessity of renal replacement therapy (descriptive
evaluation, after surgery until postoperative day-3
dichotomic measure: yes/no)
Methods/design
This is a single-centre, phase II clinical trial in patients
undergoing major abdominal surgery (Fig. 1). The study
follows a prospective, controlled and open design. Initially,
the study will begin with a pilot phase of six patients
followed by a randomization phase. An overview of the
patients’ schedule of activities according to the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) figure is provided in Fig. 2.
Pilot phase
The first six patients will receive Jonosteril® together
with sodium glycerophosphate (IMP1/IMP2 protocol) in
concentrations ranging from 1 to 6 mmol/l (Na+: 139–
149 mmol/l) to evaluate the most suitable concentration
for the following randomization phase. We will test a
concentration of 4 mmol/l phosphate (= 2 ml sodium
glycerophosphate per 500 ml Jonosteril®) initially. This
solution will contain 145 mmol/l sodium. Repeated mea-
surements of serum phosphate levels will shed light on
the efficacy of the measure. In the case that serum phos-
phate levels do not remain stable within the normal
range, we will gradually adapt the dose until stable levels
are achieved. Patients will not receive a concentration
higher than 6 mmol/l since then the sodium levels
would surpass the maximum threshold value.
Randomization phase
After the pilot phase, in which the most suitable phos-
phate concentration is determined, a total of 42 patients,
21 per group, will be allocated to one of the two study
arms by randomization:
 Jonosteril® and sodium glycerophosphate (IMP1/
IMP2) (treatment group)
 Jonosteril® (IMP1) (control group)
All patients will receive the study medication accord-
ing to their allocation over 120 min after the initiation
of general anaesthesia in a maximum dose of 30 ml per
ideal bodyweight (IBW = height (in cm) − 100) per hour
for losses due to insensible perspiration, urinary output
and extracellular deficits due to the fasting state as well
as five times the estimated blood loss [32, 33]. The
rationale for the use of the amount of fluids is based on
previous studies and the demand-oriented current
clinical practice. This is in concordance with previous
studies using similar regimes. The recruited patients
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have a higher fluid demand [32, 33]. Hofmann-Kiefer
et al. showed that a maximum of 30 ml/kg/bodyweight
was necessary to keep patients hemodynamically stable
and distinct acid-base alterations were described. Over
the time course of 120 min, the patients likely suffer
from a blood loss of 1000 ml or more. According to
current clinical practice, a blood loss should be replaced
in a ratio of 4–5:1 with crystalloids [33]. Taken together,
our approach using 30 ml/kg/ideal bodyweight seems
reasonable for this patient cohort. Measurements will
take place every 30 min: baseline (T1), 30 min (T2),
60 min (T3), 90 min (T4) and 120 min (T5) and parame-
ters will be documented by the investigators in the Case
Report Forms (CRF) of each participant. An overview of
the parameters assessed in this study and their respect-
ive time points is provided in Table 1.
Anaesthesiologic management and postoperative care
All patients will receive anaesthesiologic management
according to the institution’s standard. This involves a
thoracic epidural anaesthesia in combination with gen-
eral anaesthesia and the placement of a central venous
line and an arterial catheter for haemodynamic monitor-
ing. In case of contraindications to neuroaxial proce-
dures patients will receive general anaesthesia and,
postoperatively, patient-controlled analgesia with
piritramide. Anaesthesia will be induced with propofol
(2 mg/kg), sufentanil (0.4 mg/kg) and rocuronium
(0.6 mg/kg) and maintained with propofol and remifen-
tanil or sevoflurane in patients with certain conditions
(e.g. cardiopulmonary diseases). The pulmonary ventila-
tion will be standardized in all patients using the
volume-controlled mode in order to keep the paCO2 at
Fig. 1 Participant flow diagram showing the organizational structure and different study groups of PALANCE
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40 ± 3 mmHg as to have as little influence on acid-base
balance as possible (controls are performed using blood
gas analysis). The epidural anaesthesia will be continued
for at least 3 days and will be combined with
nonsteroidal anti-inflammatory drugs. Intraoperative
hemodynamic monitoring will be performed using a
PulsioFlex monitor with ProAQT® sensor (PULSION
Medical Systems SE, Germany). The observation period
will be 120 min after initiation of anaesthesia although
surgery will take longer in most cases. The administra-
tion of the study drug, e.g., sodium glycerophosphate, as
well as study-specific blood draws, will take place only
during the 120 min of the procedure. Afterwards, the
anaesthetist responsible for the patient will continue
according to clinical standards. All patients will be
transferred from the operating room to the ICU for
postoperative surveillance and will be visited by in-
hospital postoperative pain management service staff
daily.
Trial population and selection criteria
Patients are identified based on their diagnosis and
scheduled surgery at the department of gynaecology. We
recruit only female patients who are scheduled for major
abdominal surgery, i.e. laparotomy. By routine, these
patients will undergo placement of a central venous line
and an arterial line. Laparoscopic or transvaginal
approaches are not included. We screen eligible patients
for study participation according to the predefined inclu-
sion and exclusion criteria and provide information
regarding the trial during a pre-operatory orientation
interview with one of the investigators of the team. We
will obtain informed consents from all participants of
the study. In addition to informed consent regarding the
participation in the study, the patient will be asked to
sign a separate informed consent for the frozen storage
and possible use of blood samples for scientific purposes
to address comments of reviewers during the publication
phase. The latter consent is independent of participation
in the study. Patients receive complete information
about the trial and enough time to consider
participation.
Inclusion criteria
Subjects must meet the following inclusion criteria to be
eligible for enrolment:
Fig. 2 Patient schedule of activities according to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure. SID Strong Ion
Difference, SUEs serious unexpected events, SUSARS severe unexpected serious adverse event, UE unexpected events, UO urinary output
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 Female patients (ASA Classification I–III) who are
scheduled for a major abdominal surgical procedure
under general anaesthesia with routinely planned
placement of a central venous and an arterial
catheter and who have given written informed
consent
 Age ≥18 years
Exclusion criteria
Subjects showing the following exclusion criteria cannot
be included in the trial:
 Participation in another clinical trial
 Patients who are not personally able to give their
informed consent
 Patients at a childbearing age without using
contraceptives
 Acute or chronic renal failure (glomerular filtration
rate <60 ml/min)
 Patients suffering from an acid-base-disturbance
(i.e. severe acidosis)
 Patients suffering from acid-base disturbances
caused by SIRS or sepsis
 Pregnancy or lactation period (pregnancy testing will
be executed at least 1 day prior to the surgical
procedure)
 Oedema, hypertonic dehydratation, hyperhidratation
 Hyperphosphata emia, hypernatraemia,
hypocalcaemia (according to the standard normal
laboratory values of the authors’ institution)
 A known hypersensitivity against the test drugs and/
or their components
 A known history or active abuse of alcohol and/or
drugs
Randomization
INPADS GmbH performs the allocation of patients to
one of the two study arms using simple, balanced
randomization via random numbers. A computer-
generated number between 0 and 1 is subsequently ana-
lysed as to whether it lies above 0.5 (allocation to IMP1)
or below 0.5 (allocation to IMP1 and IMP2 combined).
The randomization procedure is executed for all patients
Table 1 Parameters measured at the distinct time points
Measurement Time point
Haemodynamic values
Norepinephrine dose (mg/h) T1–T5
Heart rate (min-1) T1–T5
Systolic blood pressure (mmHg) T1–T5
Diastolic blood pressure (mmHg) T1–T5
Central venous pressure (mmHg) T1–T5
Stroke volume variation (%) T1–T5
Cardiac output (ml/min) T1–T5
Blood loss (ml) T1–T5
Haemoglobin (g/dl) T1–T5
Haematocrit (%) T1–T5
Urine volume (ml) T1–T5
Crystalloid administered (ml) T1–T5
Serum electrolytes
[PO4
3-] ionized (mmol/l) T0–T5
[PO4
3-] (mg/dl) T0–T5
[Na+] (mmol/l) T1–T5
[K+] (mmol/l) T1–T5
[Cl−] (mmol/l) T1–T5
[Mg2+] (mmol/l) T1–T5
[Ca2+] (mmol/l) T1–T5
Osmolality (mosmol/l) T1–T5
Renal function
Serum creatinine (mg/dl) T0 and T6
Serum urea nitrogen (mg/dl) T0 and T6
GFR calculated (ml/min) T0 and T6
Acid-base values
Anion gap (mmol/l) T1–T5
HCO3- (mmol/l) T1–T5
BE (mmol/l) T1–T5
pH T1–T5
PaCO2 (mmHg) T1–T5
Stewart acid-base parameters
[A-] (mmol/l) T1–T5
Strong Ion Difference (mmol/l) T1–T5
Effective Strong Ion Difference T1–T5
Strong Ion Gap (mmol/l) T1–T5
Albumin (mg/dl) T1–T5
Lactate (mmol/l) T1–T5
Urine
[Urinary Na+] (mmol/l) T1 and T5
[Urinary K+] (mmol/l) T1 and T5
[Urinary Cl−] (mmol/l) T1 and T5
[Urinary Mg2+] (mmol/l) T1 and T5
Table 1 Parameters measured at the distinct time points
(Continued)
[Urinary Ca2+] (mmol/l) T1 and T5
[Urine osmolality] (mosmol/l) T1 and T5
[Urinary phosphate] (mmol/l) T1 and T5
Glycocalyx components
Syndecan-1 T1–T5
Hyaluronic acid T1–T5
BE base excess, GFR glomerular filtration rate
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after the pilot phase undergo the randomization
procedure and a list is generated prior to first patient’s
first visit (FPFV).
Statistical evaluation
Power considerations
This study aims to show that [A−] can be stabilized by
applying IMP1/IMP2 in a combined approach. In a pre-
vious investigation of our group, [A−] was reduced by
2.67 ± 2.4 mmol/l in patients who had received 4000 ml
of Jonosteril® over 120 min [22]. We expect that we can
counteract the decrease in [A−] up to 60% when using
the IMP1/IMP2 protocol. This will presumably result in
an average difference in [A−] of 1.602 mmol/l in the
treatment group. Furthermore, we assume that [A−] will
be more stable over all time points. As a consequence,
the range of [A−] will be lower in the treatment
compared to the control group. Therefore, we expect
that the standard deviation will rather be 1.8 mmol/l
than 2.4 mmol/l (estimated reduction of 30%) [22].
Sample size calculation
We calculated the sample size using the statistic soft-
ware SAS (SAS Institute GmbH, Heidelberg, Germany).
This study has an explorative character and is supposed
to deliver first-ever data. There is currently no compara-
tive data available for the medication group or time in-
tervals considered. For the control group regimen, there
is data available from a previous study [22] for two time
points (60 min and 120 min after exposure). Therefore,
we considered the deviation of [A−] at the time point T5
(120 min) compared to baseline T1 (0 min) applying a t
test. We expect normally distributed data since the con-
trol group data derived from the previous study showed
the same characteristics [22]. We set the level of signifi-
cance to 5% and the power to 80% resulting in 21
patients per group. With the addition of swix patients
for the pilot phase, the total number of patients is 48.
Analysis procedure
The primary objective of the study is to show that dur-
ing the observation period of 120 min the mean values
of [A−] display a lower deviation in the treatment group
when compared to the control. We will evaluate normal
distribution using the Kolmogorov-Smirnov test. To test
for differences between two study groups with normally
distributed data, a two-sample t test will be used. In
order to evaluate differences of [A−] within one study
group over time, we will perform a RM-ANOVA with a
t test for paired samples as post hoc. We will analyse
data that does not follow a normal distribution using the
Friedman test. Level of significance for all calculations is
defined at 5%. We will analyse secondary parameters de-
scriptively and calculate mean, number, minimum,
maximum, 1st quartile, 3rd quartile, mean standard
error and standard deviation (SD) (method of aggrega-
tion: continuous). Further analyses and testing proce-
dures can be defined at a later stage. The primary
statistical analysis is based on the “intention-to-treat”
principle. Safety data (UE, SUE, SUSARs) will be ana-
lysed descriptively in all groups at least every 12 months.
Data handling and dropouts
INPADS GmbH will perform data management accord-
ing to the DEGL and DMP. All patients who drop out
will be listed, followed-up and monitored. We will docu-
ment the reason for dropping out and all data registered
until then will be included in the analysis. After inclu-
sion of six patients, we will perform an interim analysis.
Although dropouts will be very unlikely, due to the de-
sign of the study, we will replace the dropout in the case
of such an event. Strategies to improve adherence to
protocols involve the participation of an investigator
(anaesthesiologist) who is responsible for the trial during
the initiation of anaesthesia and in the observation
period as well as for the completion of checklists in
similar format of the CRF. Since patients are under
anaesthesia during the intervention, other strategies,
such as patient focused techniques, are not intended.
Ethics and Good Clinical Practice
The trial will be conducted in accordance with the
Clinical Trials Directive 2001/20/EC of the European
Parliament and of the Council, the International
Conference on Harmonization guidance regarding Good
Clinical Practice (ICH-GCP E6 R1), the relevant national
regulations and the Declaration of Helsinki. Monitoring
is independent from the sponsor and competing inter-
ests. If external auditing is demanded by an authority, it
will be independent from investigators and sponsor. Any
modifications to the protocol will be, and have been, im-
mediately communicated to all responsible authorities.
Discussion
Although there is currently a broad variety of so-called
balanced crystalloid preparations available, none of them
is ideal and capable of stabilizing the patient’s acid-base
balance. This is due to the nature of their composition.
Stewart’s concept of acid-base homeostasis may provide
a new approach to improve the daily clinical routine of
fluid administration. By administering sodium glycero-
phosphate pre-emptively, it is hypothesized that stable
values of [A−] can be maintained in patients in the need
for larger amounts of fluids due to illness or type of sur-
gery. Furthermore, by supplementing phosphate perio-
peratively, a frequently occurring hypophosphatemia can
be avoided. This trial will increase our knowledge in the
applicability of Stewart’s concept of acid-base as well as
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in the field of perioperative fluid substitution, an area
that has a broad applicability in medicine and is directly
linked to the patients’ outcome.
Trial status
Recruiting: participants are currently being recruited
and enrolled.
SPIRIT guidelines
The PALANCE study protocol was written in accord-
ance with the Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT). A completed
SPIRIT Checklist (Additional file 1) and a SPIRIT figure
(Fig. 2) has been included in this manuscript.
Additional file
Additional file 1: SPIRIT Checklist. (PDF 175 kb)
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